Talk

We are very pleased to see that Navigenics and 23andMe have reached a resolution with the State of California that allows their businesses to move forward with clarity offering their personal genome services to California residents.

It’s great news for all– for consumers, the industry, and best of all– for innovation.

As promised, here’s a round-up of media on the new personal genome services.

Commentary:

• Wired’s cover story by Thomas Goetz: 23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics
• The New York Times, Amy Harmon’s early testing experience: My Genome, Myself: Seeking Clues in DNA
• The Economist, to see how others see us: Within Spitting Distance
• The Guardian, with an interesting tangent on the Native American reverence for spit: Google gives new gene mapping service a bit of spit and polish

Straight news coverage:

• The Washington Post/Reuters News: Google-funded 23andMe offers $999 DNA test
• The San Jose Mercury News, mentions GeneTree as an established, ancestry-only social networking competitor: Start-up enables users to examine their own DNA
• The Times of India: Now, check out your DNA online

The media is coming in fairly mixed. So how about you? Would you take one of these tests?

Technorati Tags: personal genome services, 23andme, decodeme, navigenics, genetic scans, genome wide arrays, media coverage

All the press and the genetics community are chattering about the almost simultaneous launch of deCODEme and 23andMe’s services a week or so ago. On my previous post, Ramunas asked me whether companies like these pose a threat to the condition-oriented testing and services that DNA Direct offers. On the contrary, I think quite the opposite. Here’s my response:

The press that these new companies are receiving is increasing people’s general awareness of genetics, risk and health. Many people may not be interested in these SNP scans, but the awareness might drive them to more significant risk issues that they are worried about — such as a cancer risk, or blood clotting risk, that’s based on personal and family history. (more…)

Holy stealth mode, Batman! While everyone’s been buzzing about Navigenics and 23andMe — how they will be offering the first genome-wide array tests soon, what will they offer, how will people react to such information — that pioneering Icelanding genetics company, deCODE, just grabbed the spotlight (again).

Today deCODE unveiled deCODEme, the first consumer service for genome-wide testing. And it looks an awful lot like what we’ve been expecting from 23andMe and Navigenics. Here’s a smattering of what people have to say about it:

I think Nicholas Wade’s phrase “sample the whole genome” is misleading, but I’ll pass on this perspective:

The significance of most variation in the human genome is presently unknown. Most of the SNPs studied so far have been identified in the course of searching for the genetic roots of common diseases, such as cancer, diabetes and heart disease. Because the diseases are common, many people possess the underlying SNPs. So any interpretation of a person’s genome is at present heavily skewed toward generating ominous news. …
There are undoubtedly genes that promote longevity and good health but far fewer of these have yet been spotted. And environmental factors, too, can affect whether certain genes are ever activated.

(more…)